Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RN7SK pseudogene 233 is classified as a *pseudogene*—a genomic DNA sequence similar to the functional RN7SK gene but presumed nonfunctional, lacking protein-coding potential or regulatory non-coding RNA function[2]. While the functional RN7SK gene encodes the 7SK small nuclear RNA, which regulates P-TEFb and transcriptional elongation[1][3], the pseudogenes in this family—including RN7SKP233—are presumed non-expressed and nonfunctional, serving as neutral evolutionary remnants. No protein, receptor, or other gene product originates from RN7SKP233, and it is not implicated as a drug target or therapeutic biomarker[2]. RN7SKP233 does not encode a protein or functional RNA and is not considered a therapeutic target. The entry should not be treated as a molecular drug target or receptor.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RN7SK pseudogene 233 (RN7SKP233).